Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ALCEDIS GmbH

Home Clinical Trial Sponsors and OrganizationsALCEDIS GmbH

ALCEDIS GmbH

Winchester Str. 3, Gießen, Hessen, Germany

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

2 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

2

50.0%

Phase 2

1

25.0%

Phase 4

1

25.0%

Trial Status Distribution

Active, not recruiting

2

50.0%

Completed

2

50.0%

Clinical Trials

Trials sponsored by this organization (4)

A single arm phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in combination with cetuximab in subjects with unresectable stage III or stage IV cutaneous squamous cell carcinoma (cSCC)

Aug 201954 participants

Evaluation of immunological effects of the RANKL-inhibitor Denosumab when administered concurrently with PD1-blocking antibodies (Nivolumab, Pembrolizumab) in patients with metastatic malignant melanoma with bone involvement

Dec 201817 participants

A study to test activity and safety of treatment with avelumab in combination with cetuximab in patients suffering from non-operable squamous cell skin cancer.

Active, not recruiting

Sep 201852 participants

Effects of a treatment with Denosumab, applied together with either Nivolumab oder Pembrolizumab, in patients with skin cancer and bone metastases

Active, not recruiting

Aug 201820 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials4
Approvals
News

Back to Organizations